Royersford, PA, United States of America

Garry Robert Smith

This inventor holds 33 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Riluzole Prodrugs. Top assignees: Biohaven Therapeutics Ltd., The Wistar Institute, Biohaven Pharmaceutical Holding Company Limited. Active years: 2013-2025.

USPTO Granted Patents = 33 (Patent Applications = 10)

% Patents Active = 90.9

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 1)

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 82(Granted Patents)

Location History:

Elverson, PA (US) (2022)
Royersford, PA (US) (2013 - 2024)
King of Prussia, PA (US) (2019 - 2024)

Company Filing History:

11 out of 32

Biohaven Therapeutics Ltd.

Biohaven Pharmaceutical Holding Company Limited

patents

4. 4 out of 9

Promentis Pharmaceuticals, Inc.

patents

5. 4 out of 1,492

Rutgers, The State University of New Jersey

patents

6. 1 out of 1

Advanced Neural Dynamics, Inc.

patent

7. 1 out of 1

Fox Chase Chemical Diversity Center, Inc.

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Riluzole Prodrugs

EBNA1 Inhibitors

Amyotrophic Lateral Sclerosis

Neuroprotective Compounds

Crystalline Forms

Substituted Derivatives

Tricyclic Azaindoles

Sulfamides

Propionic Acids

Pharmaceutical Applications

Drug Formulations

Chemical Compounds

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12472165 - Riluzole prodrugs and their use (2025-11-18),

2. 12343347 - Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis (2025-07-01),

3. 12295942 - Riluzole prodrugs and their use (2025-05-13),

4. 12258314 - EBNA1 inhibitors and their method of use (2025-03-25),

5. 12213965 - Riluzole prodrugs and their use (2025-02-04),

6. 12172974 - Prodrugs of riluzole and their method of use (2024-12-24),

7. 12116359 - EBNA1 inhibitor crystalline forms, and methods of preparing and using same (2024-10-15),

8. 12005047 - Riluzole prodrugs and their use (2024-06-11),

9. 12005046 - Riluzole prodrugs and their use (2024-06-11),

10. 11912659 - EBNA1 inhibitors and methods using same (2024-02-27),

11. 11911369 - Prodrugs of riluzole and their method of use (2024-02-27),

12. 11440893 - Prodrugs of riluzole and their method of use (2022-09-13),

13. 11242338 - EBNA1 inhibitor crystalline forms, and methods of preparing and using same (2022-02-08),

14. 11242317 - EBNA1 inhibitors and their method of use (2022-02-08),

15. 11197864 - Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis (2021-12-14),

Title: Garry Robert Smith: Innovator in Pharmaceutical Compositions

Introduction

Garry Robert Smith, based in Royersford, PA, is a prolific inventor with 28 patents to his name. His innovative contributions, particularly in the field of pharmaceuticals, focus on developing advanced therapies for various cancers.

Latest Patents

Smith's latest patents include groundbreaking compositions involving riluzole prodrugs, which are designed for the treatment of several types of cancer such as melanoma, breast cancer, brain cancer, and prostate cancer. These compositions are engineered to enhance stability during hepatic metabolism and facilitate effective oral administration, subsequently releasing riluzole into the bloodstream through enzymatic or biophysical processes. This innovative approach not only improves the therapeutic efficacy but also optimizes patient outcomes.

Career Highlights

Throughout his career, Garry Robert Smith has made significant strides in the pharmaceutical industry. He has been associated with reputable companies, including Biohaven Therapeutics Ltd. and Biohaven Pharmaceutical Holding Company Limited. His expertise and dedication have been instrumental in pushing the boundaries of cancer treatment methodologies.

Collaborations

Smith has collaborated with notable professionals in the field, including Allen B. Reitz and Jay Edward Wrobel. These partnerships have fostered an environment of innovation and shared knowledge, enhancing the development of effective cancer therapies.

Conclusion

Garry Robert Smith's contributions to pharmaceutical science are noteworthy, particularly with his innovative work on riluzole prodrugs. His ongoing commitment to cancer research not only reflects his expertise but also demonstrates the profound impact that dedicated inventors have on advancing healthcare solutions. It is through the relentless pursuit of innovation that significant improvements in patient care can be achieved.